| 1 |
Harhay MO, Casey JD, Clement M, et al. Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop [J]. Intensive Care Med, 2020, 46(5): 930-942.
|
| 2 |
Santacruz CA, Pereira AJ, Celis E, et al. Which multicenter randomized controlled trials in critical care medicine have shown reducedmortality? A systematic review [J]. Crit Care Med, 2019, 47(12): 1680-1691.
|
| 3 |
Tonelli AR, Zein J, Adams J, et al. Effects of interventions onsurvival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses [J]. Intensive Care Med, 2014, 40(6): 769-787.
|
| 4 |
Opal SM, Dellinger RP, Vincent JL, et al. The nextgeneration of sepsis clinical trial designs: what is next after the demise ofrecombinant human activated protein C? [J]. Crit Care Med, 2014, 42(7): 1714-1721.
|
| 5 |
Naylor CD. Meta-analysis and the meta-epidemiology of clinical research [J]. BMJ, 1997, 315(7109): 617-619.
|
| 6 |
Sterne JA, Jüni P, Schulz KF, et al. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research [J]. Stat Med, 2002, 21(11): 1513-1524.
|
| 7 |
Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study [J]. BMJ, 2008, 336(7644): 601-605.
|
| 8 |
Bae JM. Meta-epidemiology [J]. Epidemiol Health, 2014, 36: e2014019.
|
| 9 |
Zhang W. Meta-epidemiology: building the bridge from research evidence to clinical practice [J]. Osteoarthritis Cartilage, 2010, 18 Suppl 2: S1.
|
| 10 |
Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research [J]. Evid Based Med, 2017, 22(4): 139-142.
|
| 11 |
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis [J]. J Clin Epidemiol, 2001, 54(10): 1046-1055.
|
| 12 |
Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles [J]. JAMA, 2004, 291(20): 2457-2465.
|
| 13 |
Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews [J]. BMJ, 2010, 340: c365.
|
| 14 |
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses [J]. Ann Intern Med, 2001, 135(11): 982-989.
|
| 15 |
Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a refection of treatmenteffect or adverse events? [J]. JAMA, 2003, 290(7): 921-928.
|
| 16 |
Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study [J]. Crit Care, 2013, 17(1): R2.
|
| 17 |
Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study [J]. BMJ, 2010, 341: c3515.
|
| 18 |
Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment effect estimates: meta-epidemiological study [J]. BMJ, 2013, 346: f2304.
|
| 19 |
Ranieri VM, Thompson BT, Barie PS, et al;Prowess Shock Study Group. Drotrecogin alfa (activated) in adults withseptic shock [J]. N Engl J Med, 2012, 366(22): 2055-2064.
|
| 20 |
Semler MW, Self WH, Wanderer JP, et al; SMART Investigators, Pragmatic Critical Care Research Group. Balancedcrystalloids versus saline in critically ill adults [J]. N Engl J Med, 2018, 378(9): 829-839.
|
| 21 |
Schulz KF. Assessing allocation concealment and blinding in randomized controlled trials: why bother? [J]. ACP J Club, 2000, 132(2): A11-A12.
|
| 22 |
Miller LE, Stewart ME. The blind leading the blind: use and misuse of blinding in randomized controlled trials [J]. Contemp Clin Trials, 2011, 32(2): 240-243.
|
| 23 |
Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials [J]. JAMA, 2002, 287(22): 2973-2982.
|
| 24 |
Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study [J]. BMJ, 2008, 336(7644): 601-605.
|
| 25 |
Odgaard-Jensen J, Vist GE, Timmer A, et al. Randomisation to protect against selection bias in healthcare trials [J]. Cochrane Database Syst Rev, 2011(4), 4: MR000012.
|
| 26 |
Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, et al. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies [J]. Int J Epidemiol, 2014, 43(4): 1272-1283.
|
| 27 |
Ghimire S, Kyung E, Kang W, et al. Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals [J]. Trials, 2012, 13: 77.
|
| 28 |
Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles [J]. JAMA, 2004, 291(20): 2457-2465.
|
| 29 |
DeAngelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors[J]. JAMA, 2004, 292(11): 1363-1364.
|
| 30 |
Dickersin K, Rennie D. The evolution of trial registries and their use to assess the clinical trial enterprise [J]. JAMA, 2012, 307(17): 1861-1864.
|
| 31 |
Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials [J]. JAMA, 2009, 302(9): 977-984.
|
| 32 |
Dechartres A, Ravaud P, Atal I, et al. Association between trial registration and treatment effect estimates: a meta-epidemiological study [J]. BMC Med, 2016, 14(1): 100.
|
| 33 |
Emdin C, Odutayo A, Hsiao A, et al. Association of cardiovascular trial registration with positive study findings: Epidemiological Study of Randomized Trials (ESORT) [J]. JAMA Intern Med, 2015, 175(2): 304-307.
|
| 34 |
Dechartres A, Trinquart L, Faber T, et al. Empirical evaluation of which trial characteristics are associated with treatment effect estimates [J]. J Clin Epidemiol, 2016, 77: 24-37.
|
| 35 |
Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome: systematic review with meta-analysis [J]. Intensive Care Med, 2018, 44(10): 1603-1612.
|
| 36 |
Moses H 3rd, Matheson DH, Cairns-Smith S, et al. The anatomy of medical research: US and international comparisons [J]. JAMA, 2015, 313(2): 174-189.
|
| 37 |
Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome [J]. Cochrane Database Syst Rev, 2012, 12: MR000033.
|
| 38 |
Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? [J]. JAMA, 2003, 290(7): 921-928.
|
| 39 |
Rosefsky JB. Results of clinical trials sponsored by for-profit vsnonprofit entities [J]. JAMA, 2003, 290(23): 3070-3071.
|
| 40 |
Bero L, Oostvogel F, Bacchetti P, et al. Factors associated with findings of published trials of drug-drug comparisons: why some statinsappear more efficacious than others [J]. PLoS Med, 2007, 4(6): e184.
|
| 41 |
Bein T, Bienvenu OJ, Hopkins RO. Focus on long-term cognitive, psychological and physical impairments after critical illness[J]. Intensive Care Med, 2019, 45(10): 1466-1468.
|
| 42 |
Dinglas VD, Faraone LN, Needham DM. Understanding patient-important outcomes after critical illness: a synthesis of recent qualitative, empirical, and consensus-related studies [J]. Curr Opin Crit Care, 2018, 24(5): 401-409.
|
| 43 |
van Werkhoven CH, Harbarth S, Bonten MJM. Adaptive designs inclinical trials in critically ill patients: principles, advantages and pitfalls [J]. Intensive Care Med, 2019, 45(5): 678-682.
|
| 44 |
Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severecommunity-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase Ⅱ trial (CIGMA study) [J]. Intensive Care Med, 2018, 44(4): 438-448.
|
| 45 |
Bothwell LE, Avorn J, Khan NF, et al. Adaptive designclinical trials: a review of the literature and Clinical Trials. gov [J]. BMJ Open, 2018, 8(2): e018320.
|
| 46 |
Bhatt DL, Mehta C. Adaptive designs for clinical trials [J]. N Engl J Med, 2016, 375(1): 65-74.
|